| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Uremia | D014511 | 33 associated lipids |
| Colitis, Ulcerative | D003093 | 24 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Kidney Failure, Chronic | D007676 | 51 associated lipids |
| Nocardia Infections | D009617 | 6 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Graft Occlusion, Vascular | D006083 | 11 associated lipids |
| Hypercalcemia | D006934 | 13 associated lipids |
| Neovascularization, Pathologic | D009389 | 39 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Dermatitis, Contact | D003877 | 59 associated lipids |
| Bacterial Infections | D001424 | 21 associated lipids |
| Pain | D010146 | 64 associated lipids |
| Autoimmune Diseases | D001327 | 27 associated lipids |
| Lupus Erythematosus, Systemic | D008180 | 43 associated lipids |
| Genital Diseases, Female | D005831 | 7 associated lipids |
| Mouth Diseases | D009059 | 5 associated lipids |
| Meningococcal Infections | D008589 | 3 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Alejandro R et al. | Combined liver-islet allotransplantation in man under FK 506. | 1991 | Transplant. Proc. | pmid:1703712 |
| FK-506 shows similar graft survival rate to cyclosporine but fewer side effects: Pitt transplant team. | 1991 | Nephrol News Issues | pmid:1720511 | |
| Ito T et al. | The mechanism of tolerance induced by a perioperative injection of bone marrow cells and a brief course of FK 506. | 1991 | Transplant. Proc. | pmid:1703716 |
| The discovery of FK-506 and U.S. development. | 1991 | Nephrol News Issues | pmid:1720512 | |
| Zheng B et al. | Effects of the new and highly active immunosuppressant, rapamycin, on lymphoid tissues and cells in vivo. | 1991 | Transplant. Proc. | pmid:1703717 |
| Mieles L et al. | Interaction between FK506 and clotrimazole in a liver transplant recipient. | 1991 | Transplantation | pmid:1721250 |
| Yabuuchi H et al. | Prominent prolongation of islet xenograft survival in combination therapy with FK 506 and 15-deoxyspergualin. | 1991 | Transplant. Proc. | pmid:1703718 |
| Habucky K et al. | The pharmacodynamics of pentobarbital following FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1721282 |
| Farghali H et al. | Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats. | 1991 | Transplant. Proc. | pmid:1721283 |
| Farghali H et al. | A biochemical and 31P-NMR investigation of the effect of FK 506 and cyclosporine pretreatment on immobilized hepatocytes perifused with ethanol. | 1991 | Transplant. Proc. | pmid:1721284 |
| Farghali H et al. | FK 506 modulates D-galactosamine-induced hepatitis in rats. | 1991 | Transplant. Proc. | pmid:1721285 |
| McCarthy SA et al. | Effects of FK 506 and cyclosporine on T-cell tolerance: inhibition of a "protective" mechanism that regulates activation-induced apoptosis in developing thymocytes. | 1991 | Transplant. Proc. | pmid:1721314 |
| Zeevi A et al. | Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. | 1991 | Transplant. Proc. | pmid:1721315 |
| Matsuura T et al. | Beneficial immunosuppressive effect of combined use of FK 506 and cyclosporine assessed by proliferative responses of cloned human T cells. | 1991 | Transplant. Proc. | pmid:1721316 |
| Jiang H et al. | Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. | 1991 | Transplant. Proc. | pmid:1721317 |
| Macleod AM and Thomson AW | FK 506: an immunosuppressant for the 1990s? | 1991 | Lancet | pmid:1702172 |
| Nakamura K et al. | The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. | 1991 | Transplant. Proc. | pmid:1721346 |
| Jain AB et al. | Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. | 1991 | Transplant. Proc. | pmid:1721347 |
| Takaya S et al. | Retransplantation of liver: a comparison of FK 506- and cyclosporine-treated patients. | 1991 | Transplant. Proc. | pmid:1721348 |
| Morel P et al. | Liver retransplantation in adults: overall results and determinant factors affecting the outcome. | 1991 | Transplant. Proc. | pmid:1721349 |
| Jain AB et al. | Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1703354 |
| Venkataramanan R et al. | Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1703355 |
| Omar G et al. | FK 506 inhibition of cyclosporine metabolism by human liver microsomes. | 1991 | Transplant. Proc. | pmid:1703356 |
| Eiras G et al. | Effects of FK 506 and cyclosporine on T-cell activation: integrin-mediated adhesion of T cells, proliferation, and maturation of cytotoxic T cells. | 1991 | Transplant. Proc. | pmid:1703357 |
| Perico N et al. | FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat. | 1991 | Transplant. Proc. | pmid:1721378 |
| Wagner K et al. | Effect of FK 506 on excretion of urinary enzymes in rats. | 1991 | Transplant. Proc. | pmid:1721379 |
| Prasad SJ et al. | In vitro effects of cyclosporine and FK 506 on the renal cortex. | 1991 | Transplant. Proc. | pmid:1721380 |
| Yamada K et al. | Short-term FK 506-induced morphological changes in rat kidneys. | 1991 | Transplant. Proc. | pmid:1721381 |
| Tai J et al. | In vivo and in vitro effect of FK 506 on rat Leydig cell function. | 1991 | Transplant. Proc. | pmid:1721409 |
| Ricordi C et al. | Human islet allotransplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721410 |
| Tze WJ et al. | Long-term survival of islet allografts in diabetic rats treated with FK 506. | 1991 | Transplant. Proc. | pmid:1721411 |
| Wang X et al. | Intraportal FK 506 improves intrahepatic islet allograft survival. | 1991 | Transplant. Proc. | pmid:1721412 |
| Vincent SH et al. | Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase. | 1991 | Biochem. Pharmacol. | pmid:1708254 |
| Kitahara S et al. | Lymphoproliferative disorders after FK 506. | 1991 | Lancet | pmid:1708846 |
| Holechek MJ | Medication review: FK 506. | 1991 | ANNA J | pmid:1708982 |
| Michnick SW et al. | Solution structure of FKBP, a rotamase enzyme and receptor for FK506 and rapamycin. | 1991 | Science | pmid:1709301 |
| Katayama Y et al. | Immunosuppressive effects of FK 506 in rat lung transplantation. | 1991 | Transplant. Proc. | pmid:1721441 |
| Yokomise H et al. | Immunosuppressive effects of FK 506 in canine lung transplantation. | 1991 | Transplant. Proc. | pmid:1721442 |
| Hasegawa S et al. | FK 506 and cyclosporine: effects and side effects in canine lung transplantation. | 1991 | Transplant. Proc. | pmid:1721443 |
| Wada H et al. | Dose response to FK 506 in canine lung transplantation. | 1991 | Transplant. Proc. | pmid:1721444 |
| Armitage JM et al. | Preliminary experience with FK506 in thoracic transplantation. | 1991 | Transplantation | pmid:1713363 |
| Lorber MI et al. | A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. | 1991 | Transplantation | pmid:1713364 |
| Abu-Elmagd K et al. | The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. | 1991 | Transplantation | pmid:1713365 |
| Takada K et al. | Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. | 1991 | J. Pharmacobio-dyn. | pmid:1713626 |
| Chen MF et al. | The influence of FK-506 on the thymus and spleen in normal C3H/He mice: flow cytometric analysis of lymphocyte subpopulations. | 1991 | Immunol. Lett. | pmid:1722778 |
| Sakai K et al. | The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents. | 1991 | Brain Res. | pmid:1723023 |
| Weaver JL et al. | Comparison of the in vitro and biophysical effects of cyclosporine A, FK-506, and mycophenolic acid on human peripheral blood lymphocytes. | 1991 | Immunopharmacol Immunotoxicol | pmid:1723084 |
| Burres NS et al. | Dunaimycins, a new complex of spiroketal 24-membered macrolides with immunosuppressive activity. III. Immunosuppressive activities of dunaimycins. | 1991 | J. Antibiot. | pmid:1723403 |
| Stötter H and Lotze MT | Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. | 1991 | Arch Surg | pmid:1726819 |
| Karlsson H and Nässberger L | FK506 lacks the ability to inhibit expression of interleukin-2 receptor beta-chain on human lymphocytes. | 1991 | J Clin Lab Immunol | pmid:1726895 |